Form 4: Tandem Diabetes Care Executive Rick Carpenter Reports Stock Transactions

Rick Carpenter, Chief Technology Officer of Tandem Diabetes Care, reports the vesting of restricted stock units and subsequent tax withholding.

Summary

• On February 18, 2025, Rick Carpenter, Chief Technology Officer of Tandem Diabetes Care, exercised restricted stock units (RSUs) and had shares withheld to cover tax obligations.
• Carpenter acquired 595 shares and 1,438 shares of common stock through the vesting of RSUs.
• A total of 245 and 591 shares were withheld by Tandem Diabetes Care to satisfy tax withholding requirements.
• Following these transactions, Carpenter directly owns 16,132 shares of common stock and 7,185 derivative securities.

Sentiment

Score: 5

Explanation: This is a neutral report of stock transactions, with no inherent positive or negative sentiment.

Industry Context

This Form 4 filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies within the medical device industry.

Comparison to Industry Standards

• Executive compensation packages including RSUs are standard practice among publicly traded companies, including medical device companies like Medtronic, Abbott, and Dexcom.
• The vesting schedules and terms of the RSUs are typical for executive compensation plans designed to align management's interests with long-term shareholder value.

Stakeholder Impact

• The transactions have a minimal direct impact on shareholders, employees, customers, suppliers, and creditors.
• The filing provides transparency regarding executive compensation and stock ownership, which can be of interest to shareholders.

Key Dates

Keywords

Tandem Diabetes Care, Rick Carpenter, Form 4, Stock Transactions, Restricted Stock Units, RSU, TNDM